These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 28640942)

  • 1. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
    Boudousquie C; Bossi G; Hurst JM; Rygiel KA; Jakobsen BK; Hassan NJ
    Immunology; 2017 Nov; 152(3):425-438. PubMed ID: 28640942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.
    Bossi G; Buisson S; Oates J; Jakobsen BK; Hassan NJ
    Cancer Immunol Immunother; 2014 May; 63(5):437-48. PubMed ID: 24531387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
    Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
    Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human leucocyte antigen class I-redirected anti-tumour CD4
    Tan MP; Dolton GM; Gerry AB; Brewer JE; Bennett AD; Pumphrey NJ; Jakobsen BK; Sewell AK
    Clin Exp Immunol; 2017 Jan; 187(1):124-137. PubMed ID: 27324616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
    Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
    Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
    Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
    Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
    Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
    BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
    Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD
    Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
    Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
    J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
    Yin W; Song Y; Liu Q; Wu Y; He R
    Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells.
    Pouw N; Treffers-Westerlaken E; Kraan J; Wittink F; ten Hagen T; Verweij J; Debets R
    Cancer Immunol Immunother; 2010 Jun; 59(6):921-31. PubMed ID: 20101507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
    Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
    Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-9 promotes the survival and function of human melanoma-infiltrating CD4(+) CD8(+) double-positive T cells.
    Parrot T; Allard M; Oger R; Benlalam H; Raingeard de la Blétière D; Coutolleau A; Preisser L; Desfrançois J; Khammari A; Dréno B; Labarrière N; Delneste Y; Guardiola P; Gervois N
    Eur J Immunol; 2016 Jul; 46(7):1770-82. PubMed ID: 27094152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.
    Straetemans T; van Brakel M; van Steenbergen S; Broertjes M; Drexhage J; Hegmans J; Lambrecht BN; Lamers C; van Der Bruggen P; Coulie PG; Debets R
    Clin Dev Immunol; 2012; 2012():586314. PubMed ID: 22400038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.
    Speiser DE; Schwarz K; Baumgaertner P; Manolova V; Devevre E; Sterry W; Walden P; Zippelius A; Conzett KB; Senti G; Voelter V; Cerottini JP; Guggisberg D; Willers J; Geldhof C; Romero P; Kündig T; Knuth A; Dummer R; Trefzer U; Bachmann MF
    J Immunother; 2010 Oct; 33(8):848-58. PubMed ID: 20842051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.
    Haas C; Krinner E; Brischwein K; Hoffmann P; Lutterbüse R; Schlereth B; Kufer P; Baeuerle PA
    Immunobiology; 2009; 214(6):441-53. PubMed ID: 19157637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.